AstraZeneca PLC (LON:AZN) shares have fallen recently with the sector on the back of fears US drugs may be made cheaper by new chairman Donald Trump.
The new president has seemingly stolen a policy from his presidential rival Hillary Clinton, says Zak Mir, Tip TV’s technical analyst.
Astra has very important cancer drug trials underway with results due next year.
The price chart shows falls in October and November and with the main support level at £38 there may be a couple of pounds more on the downside before bargain hunters appear says Mir.
